Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 150-157

  Boltz, David A ^a   Ilyushina, Natalia A ^a   Arnold, C Shane ^b   Babu, Y Sudhakar ^b   Webster, Robert G ^a,c   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibody; H5N1 influenza virus; Neuraminidase inhibitor; Parenteral administration; Peramivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; PERAMIVIR; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BRAIN; CELL LINE; CHICK EMBRYO; CYCLOPENTANES; DOGS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; NEURAMINIDASE; SURVIVAL; VIRAL PROTEINS;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 53249125778     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.012     Document Type: Article

References (50)

1. Babu Y.S., Chand P., Bantia S., Kotian P.L., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliot A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., and Montgomery J.A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43 (2000) 3482-3486
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellog D.L., and Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45 (2001) 1162-1167
3. Bantia S., Arnold C.S., Parker C.D., Upshaw R., and Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69 (2006) 39-45
4. Barroso L., Treanor J., Gubareva L., and Hayden F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 10 (2005) 901-910
5. Baum E.Z., Wagaman P.C., Ly I., Turchi I., Le J., Bucher D., and Bush K. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res. 59 (2003) 13-22
6. Baz M., Abed Y., and Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74 (2007) 159-162
7. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y., and Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353 (2005) 1374-1385
8. Buchy P., Mardy S., Vong S., Toyoda T., Aubin J.T., Miller M., Touch S., Sovann L., Dufourcq J.B., Richner B., Tu P.V., Tien N.T., Lim W., Peiris J.S., and Van der Werf S. Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39 (2007) 164-168
9. Burger R.A., Billingsley J.L., Huffman J.H., Bailey K.W., Kim C.U., and Sidwell R.W. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology 47 (2000) 45-52
10. Calfee D.P., Peng A.W., Hussey E.K., Lobo M., and Hayden F.G. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir. Ther. 4 (1999) 143-149
11. Cass L.M., Efthymiopoulos C., and Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36 Suppl 1 (1999) 1-11
12. Chotpitayasunondh T., Ungchusak K., Hanshaoworakul W., Chunsuthiwat S., Sawanpanyalert P., Kijphati R., Lochindarat S., Srisan P., Suwan P., Osotthanakorn Y., Anantasetagoon T., Kanjanawasri S., Tanupattarachai S., Weerakul J., Chaiwirattana R., Maneerattanaporn M., Poolsavathitikool R., Chokephaibulkit K., Apisarnthanarak A., and Dowell S.F. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 11 (2005) 201-209
13. Chutinimitkul S., Bhattarakosol P., Srisuratanon S., Eiamudomkan A., Kongsomboon K., Damrongwatanapokin S., Chaisingh A., Suwannakarn K., Chieochansin T., Theamboonlers A., and Poovorawan Y. H5N1 influenza A virus and infected human plasma. Emerg. Infect. Dis. 12 (2006) 1041-1043
14. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3 (1994) 1687-1696
15. Cox D.R. Regression models and life-tables. J. R. Stat. Soc. B 34 (1972) 187-220
16. de Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., Beld M., Le T.P., Truong H.K., Nguyen V.V., Tran T.H., Do Q.H., and Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352 (2005) 686-691
17. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha do Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., and Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12 (2006) 1203-1207
18. Drusano G.L., Preston S.L., Smee D., Bush K., Bailey K., and Sidwell R.W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. 45 (2001) 2115-2118
19. Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M., Peng A.W., Alvord W.G., Strober W., and Straus S.E. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 180 (1999) 586-593
20. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., and Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45 (2001) 2723-2732
21. Govorkova E.A., Ilyushina N.A., Boltz D.A., Douglas A., Yilmaz N., and Webster R.G. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51 (2007) 1414-1424
22. Gu J., Xie Z., Gao Z., Liu J., Korteweg C., Ye J., Lau L.T., Lu J., Gao Z., Zhang B., McNutt M.A., Lu M., Anderson V.M., Gong E., Yu A.C., and Lipkin W.I. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370 (2007) 1137-1145
23. Hayden F.G., Cote K.M., and Douglas R.G. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17 (1980) 865-870
24. Hoffmann E., Stech J., Guan Y., Webster R.G., and Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146 (2001) 2275-2289
25. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc. Natl. Acad. Sci. USA 102 (2005) 12915-12920
26. Hurt A.C., Selleck P., Komadina N., Shaw R., Brown L., and Barr I.G. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73 (2007) 228-231
27. Ilyushina N.A., Hoffmann E., Salomon R., Webster R.G., and Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12 (2007) 363-370
28. Kilpatrick J.M., Harman L.A., Collis P.J., Aitee G., Mead E., and Alexander W.J. Pharmacokinetics and safety of peramivir by intramuscular administration. Options for the Control of Influenza VI. Toronto, Canada (2007) 231
29. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
30. Leneva I.A., Roberts N., Govorkova E.A., Goloubeva O.G., and Webster R.G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48 (2000) 101-115
31. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., Nguyen D.C., Szretter K.J., Chen L.M., Thawatsupha P., Chittaganpitch M., Waicharoen S., Nguyen D.T., Nguyen T., Nguyen H.H., Kim J.H., Hoang L.T., Kang C., Phuong L.S., Lim W., Zaki S., Donis R.O., Cox N.J., Katz J.M., and Tumpey T.M. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79 (2005) 11788-11800
32. McKimm-Breschkin J.L. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat. Respir. Med. 4 (2005) 107-116
33. McKimm-Breschkin J.L., Selleck P.W., Usman T.B., and Johnson M.A. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13 (2007) 1354-1357
34. Mishin V.P., Hayden F.G., and Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 (2005) 4515-4520
35. Potier M., Mameli L., Bélisle M., Dallaire L., and Melançon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979) 287-296
36. Reed L.J., and Muench H. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 493-497
37. Saad M.D., Boynton B.R., Earhart K.C., Mansour M.M., Niman H.L., Elsayed N.M., Nayel A.L., Abdelghani A.S., Essmat H.M., Labib E.M., Ayoub E.A., and Monteville M.R. Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. Options for the Control of Influenza VI. Toronto, Canada (2007) 228
38. Schunemann H.J., Hill S.R., Kakad M., Bellamy R., Uyeki T.M., Hayden F.G., Yazdanpanah Y., Beigel J., Chotpitayasunondh T., Del Mar C., Farrar J., Tran T.H., Ozbay B., Sugaya N., Fukuda K., Shindo N., Stockman L., Vist G.E., Croisier A., Nagjdaliyev A., Roth C., Thomson G., Zucker H., Oxman A.D., and WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7 (2007) 21-31
39. Sidwell R.W., and Smee D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 48 (2000) 1-16
40. Sidwell R.W., Huffman J.H., Barnard D.L., Bailey K.W., Wong M.H., Morrison A., Syndergaard T., and Kim C.U. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37 (1998) 107-120
41. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., and Babu Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 45 (2001) 749-757
42. Sidwell R.W., Smee D.F., Bailey K.W., and Burger R.A. Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice. Int. Immunopharmacol. 1 (2001) 1211-1218
43. Smee D.F., Huffman J.H., Morrison A.C., Barnard D.L., and Sidwell R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45 (2001) 743-748
44. Uiprasertkul M., Puthavathana P., Sangsiriwut K., Pooruk P., Srisook K., Peiris M., Nicholls J.M., Chokephaibulkit K., Vanprapar N., and Auewarakul P. Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis. 11 (2005) 1036-1041
45. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., Uiprasertkul M., Boonnak K., Pittayawonganon C., Cox N.J., Zaki S.R., Thawatsupha P., Chittaganpitch M., Khontong R., Simmerman J.M., and Chunsutthiwat S. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352 (2005) 333-340
46. Venables W.N., and Ripley B.D. Modern Applied Statistics (1997), Springer, New York, NY pp. 223-242, 297-321, 345-350.
47. World Health Organization, 2008. H5N1 avian influenza: timeline of major events. World Health Organization. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_02_15/en/index.html.
48. Yen H.L., Monto A.S., Webster R.G., and Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192 (2005) 665-672
49. Yuen K.Y., Chan P.K., Peiris M., Tsang D.N., Que T.L., Shortridge K.F., Cheung P.T., To W.K., Ho E.T., Sung R., and Cheng A.F. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 351 (1998) 467-471
50. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., Dziuba N., Holbrook M.R., Zhang L., Kilpatrick J.M., Arnold C.S., and Paessler S. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374 (2008) 198-209